Repligen Corp (RGEN)
Nasdaq · Common stock · Biological Products, (no Diagnostic Substances)
As of Oct 21, 9:58 AM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow RGEN in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on RGEN and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
RGEN at a glance
Key statistics
$11.36B
Market capitalization
- Previous close
- $178.88
- Open
- $173.87
- Day range
- $173.03 – $183.09
- Volume
- 45.6K
- Average volume (30 sessions)
- 1.21M
- Shares outstanding
- 56.44M
- Price / earnings
- 273.4
- Earnings per share
- $0.65
- Price / book
- 5.4
- Price / sales
- 14.5
- Beta (1 year, vs SPY)
- 1.19
Where the price sits in its year
52-week range
81% of the range
- Below the 52-week high
- -9.3%
- Above the 52-week low
- +78.6%
Completed sessions through Oct 20, 2026
Technical snapshot
Above its 50-day and 200-day averages
- 20-day average
- $180.75-1.0%
- 50-day average
- $176.35+1.4%
- 200-day average
- $144.26+24.0%
Between the conventional 30 and 70 bands.
+2.0%
1 week
-1.0%
1 month
+27.7%
3 months
+9.2%
Year to date
+17.2%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with RGEN
RGEN on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on RGEN.
See the plans →
Every planScreen names like RGEN
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on RGEN
Put RGEN on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on RGEN
See whether there is an open premium alert on RGEN, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
RGEN headlines
- Repligen Announces Publication of the Company’s 2023 Corporate Sustainability Report
GlobeNewswire Inc. · Dec 12, 2024
- Repligen Announces CEO Transition Plan
GlobeNewswire Inc. · Jun 13, 2024
- Repligen Corporation to Present at Upcoming June Investor Conferences
GlobeNewswire Inc. · May 22, 2024
- Repligen Corporation to Present at Upcoming May Investor Conferences
GlobeNewswire Inc. · May 7, 2024
- Repligen Reports First Quarter 2024 Financial Results
GlobeNewswire Inc. · May 1, 2024
- Repligen to Report First Quarter 2024 Financial Results
GlobeNewswire Inc. · Apr 17, 2024
- Repligen Appoints Maggie A. Pax to Board of Directors
GlobeNewswire Inc. · Mar 19, 2024
- What's Going On With Life Science-Focused Repligen Stock Today?
Benzinga · Feb 21, 2024
SEC Form 4, most recent first
Insider filings
Douglass Brian Robb
+700
CHIEF PRODUCT OFFICER · Grant or award
· Oct 6, 2026
Douglass Brian Robb
+675
CHIEF PRODUCT OFFICER · Grant or award
· Oct 6, 2026
Loeillot Olivier
+4.2K
Chief Executive Officer, Director · Option exercise
$651.14K · Oct 5, 2026
Loeillot Olivier
−4.2K
Chief Executive Officer, Director · Option exercise
· Oct 5, 2026
Loeillot Olivier
−4.2K
Chief Executive Officer, Director · Open-market sale
$798.38K · Oct 5, 2026
Loeillot Olivier
−1.3K
Chief Executive Officer, Director · Open-market sale
$238.27K · Oct 5, 2026
Loeillot Olivier
−1.2K
Chief Executive Officer, Director · Shares withheld for tax
$226.76K · Oct 2, 2026
Garland Jason K
−421
CFO · Shares withheld for tax
$79.86K · Sep 25, 2026
About Repligen Corp
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration and fluid management is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
- Exchange
- Nasdaq
- Security
- Common stock
- Industry
- Biological Products, (no Diagnostic Substances)
- Headquarters
- Waltham, MA
- Employees
- 2,000
- Listed since
- Apr 29, 1986
- Website
- repligen.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.